De novo solid malignancies after cardiac transplantation

Goldstein, Daniel J.; Williams, Deborah; Öz, Mehmet C.; Weinberg, Alan; Rose, Eric A.; Michler, Robert E.

doi:10.1016/0003-4975(95)00782-2

Cited by 63 publications

(54 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This has been reported in renal, 1 bone marrow, 2 heart, 3 and liver [4][5][6][7][8] transplant recipients and is related to an increased number of nonmelanoma skin cancers 9 and lymphomas. 5,6 Although immunosuppression has a central role in the development of cancer, the risk for de novo tumor after orthotopic liver transplantation (OLT) has not been well studied.…”

mentioning

confidence: 98%

Risk factors for development of de novo neoplasia after liver transplantation

Xiol

Guardiola²,

Menéndez

et al. 2001

Liver Transplantation

View full text Add to dashboard Cite

Liver transplant recipients are at greater risk for de novo neoplasia, especially lymphoma and nonmelanoma skin cancer; however, risk factors for this complication have not been well studied. Clinical and pathological records of 137 consecutive liver transplant recipients who had survived for at least 1 year were reviewed to register de novo neoplasia. Ten variables were analyzed for their association with the development of de novo malignancies by means of a log-rank test and stepwise selection in a multivariate analysis using the Cox proportional hazard model. Thirty de novo neoplasias appeared in 22 of 137 transplant recipients between 12 and 104 months after orthotopic liver transplantation (OLT; median follow-up, 69 months): 14 patients had 21 skin cancers, 6 patients had solid-organ cancer, and 3 patients developed a lymphoproliferative disease. Probabilities of de novo neoplasia were 13% at 5 years post-OLT and 26% at 8 years post-OLT. The only associated risk factor for any neoplasia was age. Age and hepatocarcinoma were independent risk factors associated with skin cancer. That hepatocarcinoma in the explanted liver is an independent risk factor for skin cancer suggests there is individual susceptibility to both neoplasias. (Liver Transpl 2001;7:971-975.)

show abstract

mentioning

confidence: 98%

Risk factors for development of de novo neoplasia after liver transplantation

Xiol

Guardiola²,

Menéndez

et al. 2001

Liver Transplantation

View full text Add to dashboard Cite

show abstract

“…13 For heart transplant recipients, the mean age of diagnosis is 43 to 47 years; which is still younger than those with classic Kaposi sarcoma. 8,14 Also, the log time of developing cancer after transplant is shorter, with a mean of 12 to 14 months. 13,14 Infection with human herpesvirus 8 has been established as the cause of this cancer, and immunosuppression plays a key role in this context.…”

Section: Kaposi Sarcomamentioning

confidence: 99%

“…8,14 Also, the log time of developing cancer after transplant is shorter, with a mean of 12 to 14 months. 13,14 Infection with human herpesvirus 8 has been established as the cause of this cancer, and immunosuppression plays a key role in this context. 8 Penn found that 60% of Kaposi sarcoma cases were nonvisceral (98% skin lesions, 2% mouth or oropharyngeal), with the remaining 40% being visceral, mainly involving the gastrointestinal tract, lungs, and lymph nodes.…”

Section: Kaposi Sarcomamentioning

confidence: 99%

“…13,14 Skin cancer Skin cancers are the most common malignancies that occur in transplant recipients, 26 comprising about 42% to 50% of the overall malignancies seen after heart transplant. 27 The mean interval between transplant and diagnosis of a skin tumor correlates with the age at transplant.…”

Section: Malignancies After Heart Transplantmentioning

confidence: 99%

“…Indications for heart transplant Rinaldi and associates 13 and Goldstein and associates 14 have both presented considerable data regarding neoplastic diseases in cardiac transplant patients. In light of their studies, cardiomyopathy was identified as the single most important pathology leading to cardiac transplant.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Untitled

Lateef

Basit²,

Abbasi³

et al. 2016

Exp Clin Transplant

View full text Add to dashboard Cite

Along with graft vasculopathy, malignancies comprise a major complication after heart transplant, with a rate of occurrence of 39.1% in 10 years. Skin cancers and posttransplant lymphoproliferative disorder are more common in adults, whereas lymphoma is more often shown in children. A major cause of malignancies after heart transplant is the use of increased doses of prophylactics needed during immunosuppressive therapy. Data, however, are scarce regarding the association between a particular immunosuppressive drug and a posttransplant malignancy. Compared with the general population, recipients have a higher incidence of malignancies after heart transplant, with an early onset and more aggressive disease. Solid tumors known to occur in heart transplant recipients include lung cancer, bladder and prostate carcinoma, adenocarcinoma of the oral cavity, stomach cancer, and bowel cancer, although the incidence is rare. The risk factors for development of a malignancy after heart transplant are the same as for the nontransplant population.

show abstract

Lung Cancer in Transplant Recipients

Ahmed

Marshall²,

Kucharczuk³

et al. 2004

Arch Surg

View full text Add to dashboard Cite

That aggressive surgical treatment of lung cancer (LC) is justified by stage-based outcome in immunosuppressed solid organ transplant recipients.Design: Case series.Setting: University hospital.Patients: Lung cancer developed in 15 patients (0.28%) among a solid organ transplant recipient population of 5400 accrued at our institution over a 25-year period.Main Outcome Measures: Smoking prevalence, subtypes and stages of LC represented, operative morbidity, and survival. Results:The mean time from transplantation to the diagnosis of LC was 76 months (range, 9-192 months). Eight patients received kidneys; 3, lungs; and 4, hearts. Only 11 patients (73%) had a smoking history (mean, 66 pack-years). The following carcinomas developed in our patient population: adenocarcinoma, 6 patients; squa-mous cell, 5; large cell undifferentiated, 2; bronchoalveolar, 1; and small cell, 1. Eight patients (53%) presented with inoperable stage IIIB or IV disease. The remaining patients presented in stages IA (n=2), IB (n=1), IIB (n=2), and IIIA (n=2); all underwent resection. No major postoperative complications occurred. All patients with stage IIIB or greater disease with or without treatment died quickly (mean survival, 1.4 months; range, 0.33-3.0 months). All patients with stage IIB or less remain alive a mean of 37 months after resection. Patients with stage IIIA survived only a mean of 6.0 months despite resection.Conclusions: Regarding LCs in transplant recipients compared with LCs in the nontransplant population, we find that (1) there is an increased incidence among nonsmokers; (2) death occurs rapidly in unresected patients; (3) resection carries a low morbidity rate; and (4) resection seems to offer a high chance of cure in those with cancers staged IIB or less.

show abstract

De novo solid malignancies after cardiac transplantation

Cited by 63 publications

References 15 publications

Risk factors for development of de novo neoplasia after liver transplantation

Risk factors for development of de novo neoplasia after liver transplantation

Untitled

Lung Cancer in Transplant Recipients

Contact Info

Product

Resources

About